Search En/Fr

Type here & click enter

SCIENTISTS

HEALTHCARE PROFESSIONALS

PATIENTS

INVESTORS

MEDIA

About Us Select Category

Nanobiotix

Executive Board

Discover our focused and experienced Management Team covering the whole pharmaceutical value chain.

LAURENT LEVY, PH.D

LAURENT LEVY, PH.D

CEO

LAURENT LEVY, PH.D

CEO

Laurent holds a doctorate in physical chemistry, specialized in nanomaterials, from the Pierre and Marie Curie University (Paris) and from the CEA (Commissariat à l’Énergie Atomique et aux Énergies Alternatives) and a DEA (advanced studies and diplomas) in physics of condensed matter from the UPVI-ESPCI (Paris). He has extensive experience in sciences and techniques related to nanotechnologies, a field in which he worked for more than 10 years. His research at the frontier of biotechnology and nanotechnologies has resulted in the development of a number of concrete applications such as NanoXray, which could open a new method for cancer treatment.

For many years, Laurent was a consultant in the development of application of nanotechnologies with large companies such as Sanofi (pharma), Guerbet (medical imaging), Rhodia (chemistry), as well as for biotechnology start-ups. Laurent is the author of 35 international scientific publications and communications, has applied for several patents and completed his training by a post-doctoral fellowship at the Institute for Lasers, Photonics and Biophotonics, SUNY (State University of New York), Buffalo, USA.

1/4
ELSA BORGHI, MD

ELSA BORGHI, MD

CMO

ELSA BORGHI, MD

CMO

Development and Medical Affairs Department Director, Elsa joined Nanobiotix in 2008, after having worked for the Oncology R&D Department of Sanofi-Aventis. She successfully managed clinical trials throughout the world of major oncology drugs up to their registrations. Elsa started working in the pharmaceutical industry in 1996 in the area of drug safety, primarily in oncology. Since 1999, she has been working on pivotal clinical trials, in particular for treatment of colon cancer, breast cancer and prostate cancer. Dr. Borghi has also worked on soft tissue sarcoma, lung cancer and Phase I trials involving chemotherapy, anti-neovascularisation agents and targeted therapies.

Elsa received her MD from the University of Cordoba, Spain – School of Medicine in March 1984 and a obtained the French equivalent in 1994 from the University of Paris V, extended by a specialisation in human genetics in 1995. In parallel to her degree in medicine, she also obtained an MSc in Biological Sciences from the University of Paris VI.

2/4
PHILIPPE MAUBERNA

PHILIPPE MAUBERNA

CFO

PHILIPPE MAUBERNA

CFO

As expert in management and development of financial and operational projects for the pharmaceutical industry, Philippe MAUBERNA (ISG-INSEAD), has been involved in several international projects (UK, Saudi Arabia, South Africa and Indonesia). Dedicated to the Life Sciences industry for more than 10 years, he has held senior Financial and Operations positions at Astellas Pharma Europe participating in the reinforcement of EMEA commercial effectiveness in Africa and in Europe, most notably this was supporting market authorization for several healthcare products.


He has also been heavily involved in financial projects for start-up launches and innovative SME development. As a consultant, he has provided strategic change management support for European pharmaceutical companies during their development phases.

3/4
BERND MUEHLENWEG, PH.D

BERND MUEHLENWEG, PH.D

CBO

BERND MUEHLENWEG, PH.D

CBO

Bernd holds a doctorate in chemistry from the Technical University of Munich, extended by management training at the St. Gallen Business School, as well as several merger/acquisition and negotiation techniques seminars. He was responsible for several negotiations and the execution of several licences and marketing contracts. Mr Muehlenweg is co-author of more than 17 publications and 2 patents.

He is a member of the Pharma Licensing Club of Germany (Pharmalizenzclub) and the Pharma Licensing Club France. More recently, Bernd was Business Development Director for Wilex AG in Munich, where he made significant contributions to position Wilex as a leader in the market of development of therapeutic molecules and diagnostic tools in oncology. He joined Nanobiotix in 2011 where he is responsible for ensuring the sustainable growth of the Company by concluding strategic alliances with partners.

4/4